Safari Flower, a Canadian cannabis cultivator, has received EU-Good Manufacturing Practice (GMP) certification for its Ontario production facility, the company confirmed today. The accreditation allows the company to export medical cannabis products to the United Kingdom and other European Union member states, subject to local import licences.
EU-GMP certification is a stringent quality standard required for pharmaceutical-grade cannabis products entering European markets. For UK patients, the certification means Safari Flower can now supply flower and extracts to the country's burgeoning medical cannabis sector, which has seen rising demand since the 2018 law change permitting specialist prescriptions.
The Ontario facility, which spans approximately 50,000 square feet, uses controlled-environment agriculture to produce consistent, high-THC strains. Safari Flower's chief executive said the certification 'validates years of investment in quality systems and clean-room protocols.' The company has not disclosed specific UK supply agreements but indicated it is in active discussions with several licensed importers and pharmacies.
Canada has emerged as a major source of medical cannabis for Europe, with producers like Tilray and Aurora having secured EU-GMP status years ago. The UK market, though still small relative to Canada's adult-use market, is forecast to grow as the NHS and private clinics expand prescribing. However, barriers remain: only a handful of NHS prescriptions have been issued, with most patients accessing cannabis through private clinics at costs of £200–£500 per month.
Analysts note that EU-GMP certification does not guarantee commercial success, as UK importers face strict Home Office licensing and packaging requirements. 'Certification is a necessary but not sufficient condition for market access,' said one sector analyst. 'Price competition from domestic producers and other Canadian exporters will also shape Safari Flower's margins.'